AU2020309681A1 - Micromolecule PI4KIIIα inhibitor composition, preparation method therefor and use thereof - Google Patents

Micromolecule PI4KIIIα inhibitor composition, preparation method therefor and use thereof Download PDF

Info

Publication number
AU2020309681A1
AU2020309681A1 AU2020309681A AU2020309681A AU2020309681A1 AU 2020309681 A1 AU2020309681 A1 AU 2020309681A1 AU 2020309681 A AU2020309681 A AU 2020309681A AU 2020309681 A AU2020309681 A AU 2020309681A AU 2020309681 A1 AU2020309681 A1 AU 2020309681A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
composition according
pao
oil
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020309681A
Other languages
English (en)
Inventor
Fude HUANG
Changping JIAO
Feng Wang
Shu Yang
Xiaojun Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuo Beta Pharmaceutical Technology Shanghai Co Ltd
Original Assignee
Nuo Beta Pharmaceutical Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuo Beta Pharmaceutical Technology Shanghai Co Ltd filed Critical Nuo Beta Pharmaceutical Technology Shanghai Co Ltd
Publication of AU2020309681A1 publication Critical patent/AU2020309681A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2020309681A 2019-07-05 2020-07-06 Micromolecule PI4KIIIα inhibitor composition, preparation method therefor and use thereof Abandoned AU2020309681A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019094831 2019-07-05
CNPCT/CN2019/094831 2019-07-05
PCT/CN2020/100377 WO2021004422A1 (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Publications (1)

Publication Number Publication Date
AU2020309681A1 true AU2020309681A1 (en) 2022-02-24

Family

ID=74115038

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020309681A Abandoned AU2020309681A1 (en) 2019-07-05 2020-07-06 Micromolecule PI4KIIIα inhibitor composition, preparation method therefor and use thereof

Country Status (15)

Country Link
US (1) US20230115711A1 (enExample)
EP (1) EP3995134A4 (enExample)
JP (1) JP2022538505A (enExample)
KR (1) KR20220071175A (enExample)
CN (2) CN118105372A (enExample)
AU (1) AU2020309681A1 (enExample)
BR (1) BR112022000155A2 (enExample)
CA (1) CA3149104A1 (enExample)
CO (1) CO2022001218A2 (enExample)
IL (1) IL289586A (enExample)
MX (1) MX2022000287A (enExample)
PE (1) PE20220942A1 (enExample)
PH (1) PH12022550254A1 (enExample)
TW (1) TW202126294A (enExample)
WO (1) WO2021004422A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685566A (zh) * 2020-12-31 2022-07-01 江苏挪贝肽医药科技有限公司 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法
US20240391942A1 (en) * 2021-09-30 2024-11-28 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. Halogenated phenylarsine oxide compound and application thereof
CN116478954B (zh) * 2023-02-14 2025-06-10 中国农业大学 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032203A1 (en) * 2001-07-10 2003-02-13 Sabatini David M. Small molecule microarrays
CN103215269B (zh) * 2007-07-05 2015-01-21 诺瓦提斯公司 用于治疗病毒感染的dsRNA
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
WO2019200043A1 (en) * 2018-04-11 2019-10-17 New Mexico Tech University Research Park Coporation Lipid prodrugs for use in drug delivery
CA3171783A1 (en) * 2020-03-31 2021-10-07 Fude HUANG Deuterated oxophenylarsine compound and use thereof
US20240391942A1 (en) * 2021-09-30 2024-11-28 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. Halogenated phenylarsine oxide compound and application thereof

Also Published As

Publication number Publication date
JP2022538505A (ja) 2022-09-02
EP3995134A4 (en) 2023-07-12
CA3149104A1 (en) 2021-01-14
PE20220942A1 (es) 2022-05-31
CN118105372A (zh) 2024-05-31
WO2021004422A1 (zh) 2021-01-14
CN114555056B (zh) 2024-01-05
EP3995134A1 (en) 2022-05-11
MX2022000287A (es) 2022-06-16
CO2022001218A2 (es) 2022-05-20
CN114555056A (zh) 2022-05-27
US20230115711A1 (en) 2023-04-13
PH12022550254A1 (en) 2023-06-26
TW202126294A (zh) 2021-07-16
KR20220071175A (ko) 2022-05-31
IL289586A (en) 2022-03-01
BR112022000155A2 (pt) 2022-04-12

Similar Documents

Publication Publication Date Title
CA2866067C (en) Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
WO2023207102A1 (en) Lipid nanoparticles
US20230115711A1 (en) MICROMOLECULE PI4KIIIalpha INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
JPH0637393B2 (ja) 抗腫瘍作用を有する薬剤
CN114980890B (zh) 可注射长效镇痛药物组合物及其制备方法和用途
WO2022160970A1 (zh) 一种不含乙醇的难溶性药物浓缩液以及由其制备的胶束溶液
CN112654626A (zh) 化合物及其用途
DK2528598T3 (en) RELATIONS TO suppress PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT
CN108310390B (zh) 多西他赛亚油酸酯及其脂肪乳剂和应用
WO2015110040A1 (zh) 苯丁酸氮芥衍生物、制备方法及应用
CN113979954A (zh) 一种替尼类抗肿瘤药物化合物及其制备方法和应用
HK40073830A (en) Micromolecule pi4kiiialpha inhibitor composition, preparation method therefor and use thereof
OA20568A (en) Micromolecule PI4Klllα inhibitor composition, preparation method therefor and use thereof.
HK40074190B (zh) 小分子PI4KIIIα抑制剂组合物、其制备方法及用途
HK40074190A (en) MICROMOLECULE PI4KIIIα INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
KR20150030725A (ko) 계피유 및 그의 주성분 신남 알데히드로 제조된 항폐암 약물 및 그의 용도
CN109985004A (zh) 氟比洛芬酯脂肪乳注射液、其制备方法及应用
SK284247B6 (sk) Lipozómový prípravok 6,9- bis[(2-aminoetyl)amino]benzo[g]izochinolín-5,10-dión dimaleátu a jeho použitie
CN116617203B (zh) 一种自乳化微乳组合物及其制备方法和应用
CN120004750B (zh) 一种无菌的双他喷他多癸二酸酯及其制备方法与用途
CN120058608B (zh) 可用于长效注射剂的喷他佐辛前药及制备方法与用途
CN115531306B (zh) 一种注射用左奥硝唑衍生物乳状制剂及其制备方法
JP7571940B2 (ja) イブプロフェンエステル誘導体およびその乳状製剤
JP6473801B2 (ja) １３種のグリセリド含む医薬組成物、製剤及びその応用
WO2011147254A1 (zh) 苯丁酰基姜黄素衍生物及其在制备抗肿瘤药物中的应用

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application